Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters









Database
Language
Publication year range
1.
Evaluating a Stone of Hope: ICER's 2019 Review of Treatments for Duchenne Muscular Dystrophy.
Brandsema, John Frederick.
J Manag Care Spec Pharm ; 26(4): 366-368, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32223600

ABSTRACT

DISCLOSURES: No funding contributed to the writing of this commentary. Brandsema reports consulting for Alexion, Audentes, AveXis, Biogen, Cytokinetics, PTC Therapeutics, Sarepta, and WaVe and has received research funding as a site investigator from Alexion, AveXis, Biogen, CSL Behring, Cytokinetics, Fibrogen, Pfizer, PTC Therapeutics, Sarepta, Summit, and WaVe.


Subject(s)
Insurance Coverage/economics , Insurance, Pharmaceutical Services/economics , Morpholinos/therapeutic use , Muscular Dystrophy, Duchenne/drug therapy , Oligonucleotides/therapeutic use , Pregnenediones/therapeutic use , Cost-Benefit Analysis , Humans , Insurance, Pharmaceutical Services/legislation & jurisprudence , Morpholinos/economics , Muscular Dystrophy, Duchenne/economics , Oligonucleotides/economics , Pregnenediones/economics , United States , United States Food and Drug Administration/legislation & jurisprudence
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL